Israel-based medical diagnostics company Check-Cap has partnered with GE Healthcare to develop and assess high-volume manufacturing for x-ray source production and assembly into Check-Cap's capsule for colorectal cancer.

The capsule uses ultra-low dose x-ray and its mechanism is based on wireless communication technologies to generate a scan of the interior of the colon as it moves naturally without disrupting the patient’s normal life.

It produces a 3D map of the inner surface of the colon which helps in the detection of polyps and cancer.

"Colorectal cancer is the second leading cause of cancer-related deaths in the US."

Check-Cap CEO Bill Densel said: "We are very excited to commence this strategic relationship with GE Healthcare as we continue our efforts to optimise the supply chain for the Check-Cap system.

"GE Healthcare is a global leader in the development, manufacturing, and distribution of diagnostic imaging agents and radio-pharmaceutical drugs and devices.

“We believe that leveraging their experience and expertise provides us with a significant opportunity to meet our goal of increasing the time and cost efficiencies of production of our capsule for use in future clinical trials and commercialisation."

Colorectal cancer is the second leading cause of cancer-related deaths in the US with one-third of the adult population withdrawing from the cancer screening test which detects colorectal cancer and precancerous polyps.

The Check-Cap system is an alternative to the recommended colorectal cancer screening which involves obstacles such as laxative bowel preparation, invasiveness, and sedation which result in the withdrawal of patients from participating in the screening.

After the completion of the partnership, both the companies are planning to collaborate to execute a high-volume manufacturing facility and distribution of the Check-Cap system.

Check-Cap is also performing a multi-centre clinical feasibility study of the capsule and is expecting to apply for a CE Mark for the Check-Cap system next year.